Lentis Intraocular Lens 의 안전성 경고

Food and Drug Administration Philippines에 따르면, 해당 안전성 경고 는 Philippines 에서 Oculentis BV 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 연번
    2017-288
  • 사례 국가
  • 사례 출처
    FDAP
  • 사례 출처 URL
  • 비고 / 경고
    Data from the Philippines is current through 2019. All of the data comes from the Food and Drug Administration Philippines, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Philippines.
  • 데이터 추가 비고
  • 원인
    Fda advisory no. 2017-288 voluntary product recall of all lentis intraocular lens with expiry date between 2017-01 and 2020-05 all concerned healthcare professionals and establishments are hereby advised by the food and drug administration (fda) regarding the voluntary product recall of all lentis intraocular lens (iol) having an expiry date between 2017-01 and 2020-05 (see photos of the product below) distributed and imported by ophthaswissmed philippines inc. ophthaswissmed received a notice of product recall from the oculentis bv, the manufacturer of the above-mentioned medical device product. oculentis received notifications of sporadic late postoperative opacification of lentis iol’s. opacification may compromise the optical transparency of the iol’s in time, potentially leading to a slow reduction in the patient’s visual acuity. studies made by the manufacturer have indicated that opacification could possibly be the result of phosphate remnants from a phosphate-containing cleaning agent used in the production. oculentis assured that all currently produced and all lentis iol’s products on the market with an expiry date of 2020-06 or later are completely unaffected and may be used safely and effectively. all concerned healthcare professionals and establishments are advised to discontinue further use, sale and distribution of the said affected medical device product. for more information and inquiries, please email us at this email address is being protected from spambots. you need javascript enabled to view it. or call the product research and standards development division of the fda - center for device regulation, radiation health and research at 857-1900 local 8301. dissemination of the information to all concerned is requested.       attachments: fda advisory no. 2017-288.Pdf.

Device

  • 모델명 / 제조번호(시리얼번호)
  • Manufacturer

Manufacturer